➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Colorcon
Mallinckrodt
Medtronic
Merck

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for GS-4997


Email this page to a colleague

« Back to Dashboard

What is the drug development status for GS-4997?

GS-4997 is an investigational drug.

There have been 9 clinical trials for GS-4997. The most recent clinical trial was a Phase 2 trial, which was initiated on February 13th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Hepatitis, Alcoholic. The leading clinical trial sponsors are Gilead Sciences, HepQuant, LLC, and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and three hundred and eighty-one international patents.

Recent Clinical Trials for GS-4997
TitleSponsorPhase
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) FibrosisGilead SciencesPhase 3
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 3
GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)Gilead SciencesPhase 2

See all GS-4997 clinical trials

Clinical Trial Summary for GS-4997

Top disease conditions for GS-4997
Top clinical trial sponsors for GS-4997

See all GS-4997 clinical trials

US Patents for GS-4997

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-4997   Get Started Free Fused heterocyclic compounds as CaM kinase inhibitors Gilead Sciences, Inc. (Foster City, CA)   Get Started Free
GS-4997   Get Started Free ASK1 inhibitor compounds and uses thereof SEAL ROCK THERAPEUTICS, INC. (Seattle, WA)   Get Started Free
GS-4997   Get Started Free Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof Gilead Apollo, LLC (Foster City, CA)   Get Started Free
GS-4997   Get Started Free Methods of treating liver disease Gilead Sciences, Inc. (Foster City, CA)   Get Started Free
GS-4997   Get Started Free Cyclobutyl-imidazolidinone compounds ELI LILLY AND COMPANY (Indianapolis, IN)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-4997

Drugname Country Document Number Estimated Expiration Related US Patent
GS-4997 Argentina AR110252 2036-11-30   Get Started Free
GS-4997 European Patent Office EP3548495 2036-11-30   Get Started Free
GS-4997 Taiwan TW201831487 2036-11-30   Get Started Free
GS-4997 Taiwan TWI651325 2036-11-30   Get Started Free
GS-4997 World Intellectual Property Organization (WIPO) WO2018102384 2036-11-30   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
Mallinckrodt
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.